NCT00561197 2013-01-04
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Ascenta Therapeutics
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT00286793 2011-06-29
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Ascenta Therapeutics
Phase 1/2 Completed
NCT00571675 2010-11-09
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Ascenta Therapeutics
Phase 2 Completed
NCT00440388 2010-08-27
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma
Ascenta Therapeutics
Phase 2 Completed
NCT00544960 2010-08-27
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
Ascenta Therapeutics
Phase 2 Completed
NCT00286806 2010-08-24
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Ascenta Therapeutics
Phase 1/2 Completed
NCT00397293 2010-08-24
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Ascenta Therapeutics
Phase 1/2 Completed
NCT00286780 2010-08-13
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
Ascenta Therapeutics
Phase 2 Completed